Straits Times Index
3,110.73 +36.47 (+1.19%) Nikkei
32,307.86 -550.45 (-1.68%) Hang Seng
16,334.37 -11.52 (-0.07%) FTSE 100
7,554.47 +40.75 (+0.54%) Bitcoin USD
44,286.07 +856.99 (+1.97%) CMC Crypto 200
914.81 +18.10 (+2.02%)
Carmat (CXT.BE)
| Previous close | 7.54 |
| Open | 7.56 |
| Bid | 6.54 x N/A |
| Ask | 7.14 x N/A |
| Day's range | 6.62 - 7.56 |
| 52-week range | 3.02 - 12.14 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CARMAT Announces the Opening of Its New Production Facility in Bois-d'Arcy, France
PARIS, December 04, 2023--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announced the opening of its second production facility ("BDA2") in Bois-d'Arcy, in the immediate vicinity of the Company's first production facility ("BDA1").
- Business Wire
CARMAT Presented Its Progress on the EFICAS Clinical Study at the 36th Journées de La Pitié in Paris
PARIS, October 23, 2023--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), announces that it has presented its progress on the EFICAS clinical trial at the 36th "Journées de La Pitié" national conference on heart and lung transplantation and circulatory assistance, organized by the cardi
- Business Wire
CARMAT Reports Its 2023 Half-Year Results and Provides an Update on Its Strategic Progress
PARIS, September 25, 2023--CARMAT reports its 2023 half-year results and provides an update on its strategic progress.
